Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug, D-0502, to see if it is safe and if it works against breast cancer.
- Breast Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You haven't received any cancer treatment in the last 30 days before starting the study.There may be additional criteria set by the study that you need to meet or avoid.You have brain tumors that are getting worse or causing symptoms, and they haven't been treated yet.You have only received a small number of treatments in the past for your advanced or metastatic disease, including chemotherapy, hormone therapy, or targeted therapy.
- Group 1: D-0502
- Group 2: D-0502 in combination with palbociclib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many volunteers have enrolled for this investigation?
"All current recruitment for this trial has been completed. This medical experiment was first publicized on March 18th, 2018 and recently updated on May 5th 2022. For those seeking alternative studies to participate in, there are presently 2600 trials aimed at recruiting breast cancer patients and 133 trails that need volunteers for D-0502 research."
How many locations are actively participating in the trial's execution?
"Currently, this research is enrolling participants from ten distinct sites. These include Aurora, Eugene and Greenville as well as other nearby regions which may be more convenient for prospective study-members to visit."
What maladies is D-0502 typically utilized to ameliorate?
"D-0502 is a pharmaceutical often prescribed to address breast malignancies, postmenopausal symptoms, and advance directives."
Are there any other studies utilizing D-0502 as a form of treatment?
"At present, 133 trials utilizing D-0502 are ongoing. Out of those studies, 16 have progressed to Phase 3 clinicals. While most investigations occur in Burgas, New jersey; there is a total of 6577 sites around the world conducting research for this medication."
Has D-0502 obtained regulatory approval from the Food and Drug Administration?
"D-0502 has only been tested in a few clinical trials, so its safety rating is 1. This indicates that there is limited evidence backing up the efficacy of this drug."
Are there any vacancies available for individuals to partake in this clinical investigation?
"At present, this medical trial is not enrolling new patients. Initially posted on March 18th 2018 and last updated on May 5th 2022, it is currently inactive. Those looking for clinical trials can find 2600 studies recruiting breast cancer patients, as well as 133 related to D-0502 which are actively admitting participants."
Share this study with friends
Copy Link
Messenger